### IRB Quarter 3 (Q3) Dashboard: 7/1/2021 – 9/30/2021

#### Average Quarterly Turnaround Time for submissions requiring approval (calendar days)*

<table>
<thead>
<tr>
<th></th>
<th>Initial Review</th>
<th>Continuing Review</th>
<th>Modifications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Full Board</strong></td>
<td>Q3 97</td>
<td>Q2 80</td>
<td>Q3 44</td>
</tr>
<tr>
<td></td>
<td>Q2 41</td>
<td></td>
<td>Q2 57</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Q2 58</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Initial Review</th>
<th>Continuing Review</th>
<th>Modifications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Expedited</strong></td>
<td>65</td>
<td>72</td>
<td>38</td>
</tr>
<tr>
<td></td>
<td>37</td>
<td></td>
<td>37</td>
</tr>
<tr>
<td></td>
<td>22</td>
<td></td>
<td>26</td>
</tr>
</tbody>
</table>

#### NCR Average Turnaround Time (calendar days) and Submission Totals

<table>
<thead>
<tr>
<th></th>
<th>Chair Avg. TAT</th>
<th>Number Submissions Chairs Reviewed</th>
<th>Designees of the Board Avg. TAT</th>
<th>Number Submissions Reviewed by Designees of Board</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Submissions:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ISMMS</strong></td>
<td>8</td>
<td>619</td>
<td>1</td>
<td>1066</td>
</tr>
</tbody>
</table>

#### Total Approved (no RNIs included):

<table>
<thead>
<tr>
<th></th>
<th>Q3 1942</th>
<th>Q2 1804</th>
<th>YTD 6311</th>
</tr>
</thead>
</table>

#### % of Approvals that Met the Service Pledge of 42 calendar days

<table>
<thead>
<tr>
<th></th>
<th>Initial Review</th>
<th>Continuing Review</th>
<th>Modifications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Full Board</strong></td>
<td>23%</td>
<td>20%</td>
<td>58%</td>
</tr>
<tr>
<td></td>
<td>65%</td>
<td></td>
<td>45%</td>
</tr>
<tr>
<td></td>
<td>39%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Initial Review</th>
<th>Continuing Review</th>
<th>Modifications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Expedited</strong></td>
<td>47%</td>
<td>26%</td>
<td>75%</td>
</tr>
<tr>
<td></td>
<td>76%</td>
<td></td>
<td>88%</td>
</tr>
<tr>
<td></td>
<td>80%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* = Green # = TAT decreased > 2 days from last quarter  
Red # = TAT increased > 2 days from last quarter  
Black # = TAT unchanged or less than 2 days changed from last quarter  
Note: All decimals are rounded up or down to the nearest whole number.
Initial Review for Full Board Projects TAT increased from 80 to 97 Calendar Days

338 Calendar Days  
STUDY-20-01329  
The delay in this review came from the study team submitting an application without the appropriate regulatory documentation (FDA letter). Study team held on to project for 277 days before re-submitting with the appropriate documentation. This went to a board meeting three weeks after the application was re-submitted and was approved.

312 Calendar Days  
STUDY-20-01496  
The delay in approving this study came from the study team taking 218 days to respond to requested modifications sent by the full board. The study team was working out the funding for the study during that time.

306 Calendar Days  
STUDY-20-01632  
The major delay in approving this study came from the study team taking 136 days to respond to requested modifications sent by the full board. This time was spent waiting for the contract to be executed for the study before a final approval letter was released.

259 Calendar Days  
STUDY-20-01988  
The IRB analyst took four weeks to send out initial pre-review comments for this study. The study team then held on to project for 132 days, due to a pending InfoSec review. The project was approved pending MRSA comments. The study team then took four weeks to respond to the MRSA comments. At that time the application was returned and approved.
Continuing Review for Full Board Projects TAT increased from 41 to 44 Calendar Days

134 Calendar Days
STUDY-10-00070-CR002
The delay in this review came from the study team holding on to the submission for 102 days during the pre-review phase.

128 Calendar Days
STUDY-19-01227-CR001
The delay in approving this study came from the study team taking 73 days to respond to pre-review comments. There were 5 rounds of pre-review as the study team was having a hard time responding to all the comments sent by the analyst.

95 Calendar Days
STUDY-15-00331-CR001
The approval was not sent for more than two months (70 days) after it was approved at the meeting because the GCO submission was not approved. When the GCO submission was approved, the team responded and we released the approval letter.
Department Codes

- AN - Anesthesiology
- CM - Preventative Medicine
- CS - Cardiothoracic Surgery
- DE - Dermatology
- EM - Emergency Medicine
- GE - Geriatrics
- GME - General Medicine
- GS - Graduate School
- HG - Genetics & Genomics Sciences
- HP - Population Health Science and Policy
- IT - Information Technology
- MCD - Developmental & Regenerative Biology
- ME-CA - Cardiology
- ME-CI - Clinical Immunology
- MED - Medical Education
- ME-EN - Endocrinology
- ME-GA - Gastroenterology
- ME-HME - Hospital Medicine
- ME-HO - Hematology/Oncology
- ME-ID - Infectious Diseases
- ME-LD - Liver Diseases
- ME-NP - Nephrology
- ME-PU - Pulmonary/Critical Care
- ME-RH - Rheumatology
- MI - Microbiology
- NE - Neurology
- NR - Nursing
- NSC - Neuroscience
- NSU - Neurosurgery
- OB - Obstetrics/Gynecology
- OP - Ophthalmology
- OR - Orthopedics
- OS - Oncological Sciences
- OT - Otolaryngology
- PA - Pathology
- PE - Pediatrics
- PHR - Pharmacy
- PS - Psychiatry
- R - Radiology
- RM - Rehabilitation Medicine
- RT - Radiation Oncology
- SU - Surgery
- UR - Urology